X0306 4 2022-08-30 0000810509 NAVIDEA BIOPHARMACEUTICALS, INC. NAVB 0001753763 Scott John K Jr. 4995 BRADENTON AVE., SUITE 240 DUBLIN OH 43017 1 1 Common Stock 2022-08-31 4 A 0 2500 0 A 8103395 D Common Stock 10139 I By spouse and children Series G Redeemable Preferred Stock 3260 D Series F Redeemable Convertible Preferred Stock 0.80 2022-08-30 4 S 0 1740 1379.31 D 2022-04-10 Common Stock 2175000 0 D Series I Convertible Preferred Stock 0.45 2022-08-30 4 P 0 2400 A 2022-08-30 Common Stock 5332800 2400 D Warrant to Purchase Common Stock 0.50 2022-08-30 4 P 0 2400 A 2022-08-30 2027-08-30 Common Stock 5332800 2400 D Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees. Issuance deferred at the request of the Reporting Person. Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares. Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was surrendered to pay the subscription price for the units purchased in the Rights Offering. The fair market value of the Series F Redeemable Convertible Preferred Stock surrendered in the Rights Offering was determined by the Issuer's board of directors based on an independent appraisal obtained by the Issuer. Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was convertible at any time and had no expiration date. The Reporting Person acquired the Series I Convertible Preferred Stock and Warrants to Purchase Common Stock pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering ("Rights Offering"), as disclosed in the Registration Statement on Form S-1, as amended, and Prospectus Supplement No. 1 filed by the Issuer with the Securities and Exchange Commission. Pursuant to the Rights Offering, the Reporting Person purchased units at a subscription price of $1,000 per unit, with each unit consisting of one (1) share of Series I Convertible Preferred Stock and one (1) Warrant to Purchase 2,222 shares of Common Stock. Series I Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date. /s/ Erika L. Eves for John K. Scott, Jr. by power of attorney 2022-09-01